L3VLUP
ProSign in

HRMY · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

HRMYJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • HRMY
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterHRMYJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 20201 holders, $3.9m32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 20211 holders, $66m33 holders, $25.2bn
Q1 20222 holders, $87m35 holders, $28.2bn
Q2 20223 holders, $92m33 holders, $26.9bn
Q3 20223 holders, $93m36 holders, $25.4bn
Q4 20225 holders, $110m35 holders, $27.6bn
Q1 20233 holders, $16m42 holders, $24.5bn
Q2 20235 holders, $35m38 holders, $25.0bn
Q3 20235 holders, $28m37 holders, $18.9bn
Q4 20234 holders, $23m31 holders, $19.0bn
Q1 20242 holders, $15m32 holders, $19.7bn
Q2 20241 holders, $2.6m35 holders, $20.4bn
Q3 20242 holders, $3.4m28 holders, $22.3bn
Q4 20243 holders, $35m37 holders, $20.4bn
Q1 20253 holders, $36m32 holders, $20.5bn
Q2 20251 holders, $38m31 holders, $18.4bn
Q3 20254 holders, $7.5m32 holders, $23.7bn
Q4 20255 holders, $111m29 holders, $27.8bn
Q1 20265 holders, $41m34 holders, $35.6bn
Q2 20263 holders, $54m33 holders, $39.1bn
HRMY

Harmony Biosciences HLDGS In

Holders
3
Reported value
$54m
Buyers
14
Sellers
18

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only HRMY (2)

PDT Partners LLC, Renaissance Technologies LLC

Only JNJ (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →